Pharmacological advances for treatment in Duchenne muscular dystrophy

Current Opinion in Pharmacology

Volumn 34, Issue , 2017, Pages 36-48

  Guiraud, Simon ^a   Davies, Kay E ^a  

^a UNIVERSITY OF OXFORD   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

5 AMINO 4 IMIDAZOLECARBOXAMIDE RIBOSIDE; ARGININE; ATALUREN; BIGLYCAN; DYSTROPHIN ASSOCIATED PROTEIN COMPLEX; EDASALONEXENT; EPICATECHIN; EZUTROMID; GENTAMICIN; GIVINOSTAT; HABEKACIN; HALOFUGINONE; HEPARIN; IDEBENONE; LOSARTAN; METFORMIN; NABUMETONE; NEU DIFFERENTIATION FACTOR; O (2 HYDROXY 3 PIPERIDINOPROPYL)NICOTINIC AMIDOXIME; PREDNISONE; QUERCETIN; REACTIVE OXYGEN METABOLITE; RESVERATROL; RIMEPORIDE; SIMVASTATIN; TAMOXIFEN; UNINDEXED DRUG; UTROPHIN; VAMOROLONE; [2 METHYL 4 [4 METHYL 2 (4 TRIFLUOROMETHYLPHENYL) 5 THIAZOLYLMETHYLTHIO]PHENOXY]ACETIC ACID; DYSTROPHIN;

CALCIUM HOMEOSTASIS; CALCIUM TRANSPORT; CODON; DISORDERS OF MITOCHONDRIAL FUNCTIONS; DRUG EFFICACY; DRUG MECHANISM; DRUG SAFETY; DUCHENNE MUSCULAR DYSTROPHY; HUMAN; MUSCLE GROWTH; MUSCLE ISCHEMIA; NEUROPATHOLOGY; NONHUMAN; OXIDATIVE STRESS; PROTEIN EXPRESSION; REVIEW; ANIMAL; DEFICIENCY; METABOLISM;

ANIMALS; DYSTROPHIN; DYSTROPHIN-ASSOCIATED PROTEIN COMPLEX; HUMANS; MUSCULAR DYSTROPHY, DUCHENNE;

EID: 85018735509     PISSN: 14714892     EISSN: 14714973     Source Type: Journal    
DOI: 10.1016/j.coph.2017.04.002     Document Type: Review

References (64)

1. 1•• Guiraud, S., Aartsma-Rus, N.M., Vieira, K.E., van Ommen, G.J., Kunkel, L.M., The pathogenesis and therapy of muscular dystrophies. Annu. Rev. Genom. Hum. Genet. 16 (2015), 281–308 A complete review about Duchenne muscular dystrophy from the identification of the dystrophin gene, the the molecular basis and pathophysiology of the disease to the extensive pre-clinical development in different animal models to the current clinical trials in DMD patients.
2. 2•• Bladen, C.L., et al. The TREAT-NMD DMD Global Database: analysis of more than 7,000 Duchenne muscular dystrophy mutations. Hum. Mutat. 36 (2015), 395–402 A great study analyzing the type and frequency of patient-specific mutations with Duchenne muscular dystrophy.
3. 3 Bach, J.R., O'Brien, J., Krotenberg, R., Alba, A.S., Management of end stage respiratory failure in Duchenne muscular dystrophy. Muscle Nerve 10 (1987), 177–182.
4. 4 Monaco, A.P., Neve, R.L., Colletti-Feener, C., Bertelson, C.J., Kurnit, D.M., Kunkel, L.M., Isolation of candidate cDNAs for portions of the Duchenne muscular dystrophy gene. Nature 323 (1986), 646–650.
5. 5 England, S.B., Nicholson, L.V., Johnson, M.A., Forrest, S.M., Love, D.R., Zubrzycka-Gaarn, E.E., Bulman, D.E., Harris, J.B., Davies, K.E., Very mild muscular dystrophy associated with the deletion of 46% of dystrophin. Nature 343 (1990), 180–182.
6. 6 Emery, A.E., Dystrophin function. Lancet, 335, 1990, 1289.
7. 7 Guiraud, S., Chen, H., Burns, D.T., Davies, K.E., Advances in genetic therapeutic strategies for Duchenne muscular dystrophy. Exp. Physiol. 100 (2015), 1458–1467.
8. 8 Robinson-Hamm, J.N., Gersbach, C.A., Gene therapies that restore dystrophin expression for the treatment of Duchenne muscular dystrophy. Hum. Genet. 135 (2016), 1029–1040.
9. 9 Niks, E., Aartsma-Rus, A., Exon skipping: a first in class strategy for Duchenne muscular dystrophy. Expert Opin. Biol. Ther. 17 (2016), 225–236.
10. 10 Politano, L., Nigro, G., Nigro, V., Piluso, G., Papparella, S., Paciello, O., Comi, L.I., Gentamicin administration in Duchenne patients with premature stop codon. Preliminary results. Acta Myol. 22 (2003), 15–21.
11. 11 Welch, E.M., et al. PTC124 targets genetic disorders caused by nonsense mutations. Nature 447 (2007), 87–91.
12. 12 Kayali, R., Ku, J.M., Khitrov, G., Jung, M.E., Prikhodko, O., Bertoni, C., Read-through compound 13 restores dystrophin expression and improves muscle function in the mdx mouse model for Duchenne muscular dystrophy. Hum. Mol. Genet. 21 (2012), 4007–4020.
13. 13 Nudelman, I., Glikin, D., Smolkin, B., Hainrichson, M., Belakhov, V., Baasov, T., Repairing faulty genes by aminoglycosides: development of new derivatives of geneticin (G418) with enhanced suppression of diseases-causing nonsense mutations. Bioorg. Med. Chem. 18 (2010), 3735–3746.
14. 14 Love, D.R., Hill, D.F., Dickson, G., Spurr, N.K., Byth, B.C., Marsden, R.F., Walsh, F.S., Edwards, Y.H., Davies, K.E., An autosomal transcript in skeletal muscle with homology to dystrophin. Nature 339 (1989), 55–58.
15. 15 Weir, A.P., Burton, E.A., Harrod, G., Davies, K.E., A- and B-utrophin have different expression patterns and are differentially up-regulated in mdx muscle. J. Biol. Chem. 277 (2002), 45285–45290.
16. 16 Tome, F.M., Matsumura, K., Chevallay, M., Campbell, K.P., Fardeau, M., Expression of dystrophin-associated glycoproteins during human fetal muscle development: a preliminary immunocytochemical study. Neuromuscul. Disord. 4 (1994), 343–348.
17. 17 Nguyen, T.M., Ellis, J.M., Love, D.R., Davies, K.E., Gatter, K.C., Dickson, G., Morris, G.E., Localization of the DMDL gene-encoded dystrophin-related protein using a panel of nineteen monoclonal antibodies: presence at neuromuscular junctions, in the sarcolemma of dystrophic skeletal muscle, in vascular and other smooth muscles, and in proliferating brain cell lines. J. Cell Biol. 115 (1991), 1695–1700.
18. 18 Burton, E.A., Tinsley, J.M., Holzfeind, P.J., Rodrigues, N.R., Davies, K.E., A second promoter provides an alternative target for therapeutic up-regulation of utrophin in Duchenne muscular dystrophy. Proc. Natl. Acad. Sci. U. S. A. 96 (1999), 14025–14030.
19. 19 Helliwell, T.R., Man, N.T., Morris, G.E., Davies, K.E., The dystrophin-related protein, utrophin, is expressed on the sarcolemma of regenerating human skeletal muscle fibres in dystrophies and inflammatory myopathies. Neuromuscul. Disord. 2 (1992), 177–184.
20. 20 Tinsley, J., Deconinck, N., Fisher, R., Kahn, D., Phelps, S., Gillis, J.M., Davies, K., Expression of full-length utrophin prevents muscular dystrophy in mdx mice. Nat. Med. 4 (1998), 1441–1444.
21. 21 Tinsley, J.M., et al. Daily treatment with SMTC1100, a novel small molecule utrophin upregulator, dramatically reduces the dystrophic symptoms in the mdx mouse. PLoS One, 6, 2011, e19189.
22. 22 Ljubicic, V., Miura, P., Burt, M., Boudreault, L., Khogali, S., Lunde, J.A., Renaud, J.M., Jasmin, B.J., Chronic AMPK activation evokes the slow, oxidative myogenic program and triggers beneficial adaptations in mdx mouse skeletal muscle. Hum. Mol. Genet. 20 (2011), 3478–3493.
23. 23•• Guiraud, S., et al. Second-generation compound for the modulation of utrophin in the therapy of DMD. Hum. Mol. Genet. 24 (2015), 4212–4224 Pre-clinical evaluation of the new generation of utrophin modulators structurally close to ezutromid but with a better exposure profile. This study validated the ezutromid series.
24. 24•• Ricotti, V., Spinty, S., Roper, H., Hughes, I., Tejura, B., Robinson, N., Layton, G., Davies, K., Muntoni, F., Tinsley, J., Safety, tolerability, and pharmacokinetics of SMT C1100, a 2-arylbenzoxazole utrophin modulator, following single- and multiple-dose administration to pediatric patients with duchenne muscular dystrophy. PLoS One, 11, 2016, e0152840 Safety profile of ezutromid (SMT C1100) in DMD patients.
25. 25 Tinsley, J., Robinson, N., Davies, K.E., Safety, tolerability, and pharmacokinetics of SMT C1100, a 2-arylbenzoxazole utrophin modulator, following single- and multiple-dose administration to healthy male adult volunteers. J. Clin. Pharmacol. 55 (2015), 698–707.
26. 26 Moorwood, C., Lozynska, O., Suri, N., Napper, A.D., Diamond, S.L., Khurana, T.S., Drug discovery for Duchenne muscular dystrophy via utrophin promoter activation screening. PLoS One, 6, 2011, e26169.
27. 27 Miura, P., Chakkalakal, J.V., Boudreault, L., Belanger, G., Hebert, R.L., Renaud, J.M., Jasmin, B.J., Pharmacological activation of PPARbeta/delta stimulates utrophin A expression in skeletal muscle fibers and restores sarcolemmal integrity in mature mdx mice. Hum. Mol. Genet. 18 (2009), 4640–4649.
28. 28 Ljubicic, V., Khogali, S., Renaud, J.M., Jasmin, B.J., Chronic AMPK stimulation attenuates adaptive signaling in dystrophic skeletal muscle. Am. J. Physiol. Cell Physiol. 302 (2012), C110–21.
29. 29 Gordon, B.S., Delgado Diaz, D.C., Kostek, M.C., Resveratrol decreases inflammation and increases utrophin gene expression in the mdx mouse model of Duchenne muscular dystrophy. Clin. Nutr. 32 (2013), 104–111.
30. 30 Ballmann, C., Hollinger, K., Selsby, J.T., Amin, R., Quindry, J.C., Histological and biochemical outcomes of cardiac pathology in mdx mice with dietary quercetin enrichment. Exp. Physiol. 100 (2015), 12–22.
31. 31 Ljubicic, V., Jasmin, B.J., Metformin increases peroxisome proliferator-activated receptor gamma Co-activator-1alpha and utrophin a expression in dystrophic skeletal muscle. Muscle Nerve 52 (2015), 139–142.
32. 32•• Peladeau, C., Ahmed, A., Amirouche, A., Crawford Parks, T.E., Bronicki, L.M., Ljubicic, V., Renaud, J.M., Jasmin, B.J., Combinatorial therapeutic activation with heparin and AICAR stimulates additive effects on utrophin A expression in dystrophic muscles. Hum. Mol. Genet. 25 (2016), 24–43 A very interesting pre-clinical study demonstrating the potential of combinatory strategies/mechanisms to enhance utrophin expression.
33. 33 Basu, U., Lozynska, O., Moorwood, C., Patel, G., Wilton, S.D., Khurana, T.S., Translational regulation of utrophin by miRNAs. PLoS One, 6, 2011, pe29376.
34. 34 Vianello, S., et al. Arginine butyrate: a therapeutic candidate for Duchenne muscular dystrophy. FASEB J. 27 (2013), 2256–2269.
35. 35 Amenta, A.R., Yilmaz, A., Bogdanovich, S., McKechnie, B.A., Abedi, M., Khurana, T.S., Fallon, J.R., Biglycan recruits utrophin to the sarcolemma and counters dystrophic pathology in mdx mice. Proc. Natl. Acad. Sci. U. S. A. 108 (2011), 762–767.
36. 36 Gibbs, E.M., Marshall, J.L., Ma, E., Nguyen, T.M., Hong, G., Lam, J., Spencer, M.J., Crosbie-Watson, R.H., High levels of sarcospan are well tolerated and act as a sarcolemmal stabilizer to address skeletal muscle and pulmonary dysfunction in DMD. Hum. Mol. Genet. 25 (2016), 5395–5406.
37. 37 Durko, M., Allen, C., Nalbantoglu, J., Karpati, G., CT-GalNAc transferase overexpression in adult mice is associated with extrasynaptic utrophin in skeletal muscle fibres. J. Muscle Res. Cell Motil. 31 (2010), 181–193.
38. 38 Vanhoutte, D., et al. Thrombospondin expression in myofibers stabilizes muscle membranes. eLife, 5, 2016.
39. 39 Blake, D.J., Weir, A., Newey, S.E., Davies, K.E., Function and genetics of dystrophin and dystrophin-related proteins in muscle. Physiol. Rev. 82 (2002), 291–329.
40. 2+]i and muscle damage in the mdx mouse. J. Physiol. 562:Pt. 2 (2005), 367–380.
41. 2+, reactive oxygen species, and nitric oxide in the development of muscular dystrophy. Physiol. Rev. 96 (2016), 253–305 A very complete review defining the early damage pathways in Duchenne muscular dystrophy.
42. 42 Spurney, C.F., et al. CINRG pilot trial of coenzyme Q10 in steroid-treated Duchenne muscular dystrophy. Muscle Nerve 44 (2011), 174–178.
43. 43•• Buyse, G.M., et al. Efficacy of idebenone on respiratory function in patients with Duchenne muscular dystrophy not using glucocorticoids (DELOS): a double-blind randomised placebo-controlled phase 3 trial. Lancet 385 (2015), 1748–1757 Results of the phase 3 study demonstrating that Idebenone treatment reduced the loss of respiratory function in DMD patients.
44. 44• Whitehead, N.P., Kim, M.J., Bible, K.L., Adams, M.E., Froehner, S.C., A new therapeutic effect of simvastatin revealed by functional improvement in muscular dystrophy. Proc. Natl. Acad. Sci. U. S. A. 112 (2015), 12864–12869 A surprising pre-clinical study demonstrating great benefits after treatment with Simvastatin.
45. 45 Robert, V., Massimino, M.L., Tosello, V., Marsault, R., Cantini, M., Sorrentino, V., Pozzan, T., Alteration in calcium handling at the subcellular level in mdx myotubes. J. Biol. Chem. 276 (2001), 4647–4651.
46. 46 Wissing, E.R., Millay, D.P., Vuagniaux, G., Molkentin, J.D., Debio-025 is more effective than prednisone in reducing muscular pathology in mdx mice. Neuromuscul. Disord. 20 (2010), 753–760.
47. 47 Messina, S., Vita, G.L., Aguennouz, M., Sframeli, M., Romeo, S., Rodolico, C., Vita, G., Activation of NF-kappaB pathway in Duchenne muscular dystrophy: relation to age. Acta Myol. 30 (2011), 16–23.
48. 48 Traynor, K., Deflazacort approved for Duchenne muscular dystrophy. Am. J. Health Syst. Pharm., 74, 2017, 368.
49. 49 Moxley, R.T. 3rd, Pandya, S., Ciafaloni, E., Fox, D.J., Campbell, K., Change in natural history of Duchenne muscular dystrophy with long-term corticosteroid treatment: implications for management. J. Child Neurol. 25 (2010), 1116–1129.
50. 50 Heier, C.R., et al. VBP15, a novel anti-inflammatory and membrane-stabilizer, improves muscular dystrophy without side effects. EMBO Mol. Med. 5 (2013), 1569–1585.
51. 51 Hammers, D.W., Sleeper, M.M., Forbes, S.C., Coker, C.C., Jirousek, M.R., Zimmer, M., Walter, G.A., Sweeney, H.L., Disease-modifying effects of orally bioavailable NF-kappaB inhibitors in dystrophin-deficient muscle. JCI Insight, 1, 2016, e90341.
52. 52 Donovan, J.M., Zimmer, M., Offman, E., Grant, T., Jirousek, M., A novel NF-kappaB inhibitor, edasalonexent (CAT-1004), in development as a disease-modifying treatment for patients with duchenne muscular dystrophy: phase 1 safety, pharmacokinetics, and pharmacodynamics in adult subjects. J. Clin. Pharmacol. 57 (2017), 627–639.
53. ® Trial for Edasalonexent (CAT-1004) in Duchenne Muscular Dystrophy. http://ir.catabasis.com/phoenix.zhtml?c=251269&p=irol-newsArticle&ID=2241021; 2017.
54. 54 Taub, R., Blocking NF-kappaB in the liver: the good and bad news. Hepatology 27 (1998), 1445–1446.
55. 55 Colussi, C., et al. HDAC2 blockade by nitric oxide and histone deacetylase inhibitors reveals a common target in Duchenne muscular dystrophy treatment. Proc. Natl. Acad. Sci. U. S. A. 105 (2008), 19183–19187.
56. 56 Minetti, G.C., et al. Functional and morphological recovery of dystrophic muscles in mice treated with deacetylase inhibitors. Nat. Med. 12 (2006), 1147–1150.
57. 57•• Bettica, P., et al. Histological effects of givinostat in boys with Duchenne muscular dystrophy. Neuromuscul. Disord. 26 (2016), 643–649 Histological results of the phase 2 study in DMD patients after one year of treatment with the HDAC inhibitor Givinostat.
58. 58 Turgeman, T., Hagai, Y., Huebner, K., Jassal, D.S., Anderson, J.E., Genin, O., Nagler, A., Halevy, O., Pines, M., Prevention of muscle fibrosis and improvement in muscle performance in the mdx mouse by halofuginone. Neuromuscul. Disord. 18 (2008), 857–868.
59. 59 McPherron, A.C., Lawler, A.M., Lee, S.J., Regulation of skeletal muscle mass in mice by a new TGF-beta superfamily member. Nature 387 (1997), 83–90.
60. 60 Bogdanovich, S., Krag, T.O., Barton, E.R., Morris, L.D., Whittemore, L.A., Ahima, R.S., Khurana, T.S., Functional improvement of dystrophic muscle by myostatin blockade. Nature 420 (2002), 418–421.
61. 61 Sander, M., Chavoshan, B., Harris, S.A., Iannaccone, S.T., Stull, J.T., Thomas, G.D., Victor, R.G., Functional muscle ischemia in neuronal nitric oxide synthase-deficient skeletal muscle of children with Duchenne muscular dystrophy. Proc. Natl. Acad. Sci. U. S. A. 97 (2000), 13818–13823.
62. 62 Hammers, D.W., Sleeper, M.M., Forbes, S.C., Shima, A., Walter, G.A., Sweeney, H.L., Tadalafil treatment delays the onset of cardiomyopathy in dystrophin-deficient hearts. J. Am. Heart Assoc., 5, 2016.
63. 63• Nelson, M.D., Rader, F., Tang, X., Tavyev, J., Nelson, S.F., Miceli, M.C., Elashoff, R.M., Sweeney, H.L., Victor, R.G., PDE5 inhibition alleviates functional muscle ischemia in boys with Duchenne muscular dystrophy. Neurology 82 (2014), 2085–2091 Proof of concept for PDE5i as a therapeutic aroach in DMD patients.
64. 64 Mahmood, I., Green, M.D., Pharmacokinetic and pharmacodynamic considerations in the development of therapeutic proteins. Clin. Pharmacokinet. 44 (2005), 331–347.